Candel Therapeutics, Inc.
CADL
$4.91
-$0.13-2.58%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 18.42M | 16.96M | 15.54M | 14.93M | 14.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 48.26M | 40.61M | 36.16M | 33.56M | 33.33M |
| Operating Income | -48.26M | -40.61M | -36.16M | -33.56M | -33.33M |
| Income Before Tax | -38.18M | -22.76M | -22.14M | -39.58M | -55.18M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -38.18 | -22.76 | -22.14 | -39.58 | -55.18 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.18M | -22.76M | -22.14M | -39.58M | -55.18M |
| EBIT | -48.26M | -40.61M | -36.16M | -33.56M | -33.33M |
| EBITDA | -47.41M | -39.69M | -35.19M | -32.57M | -32.34M |
| EPS Basic | -0.69 | -0.55 | -0.68 | -1.33 | -1.75 |
| Normalized Basic EPS | -0.43 | -0.34 | -0.42 | -0.83 | -1.10 |
| EPS Diluted | -0.71 | -0.56 | -0.69 | -1.34 | -1.75 |
| Normalized Diluted EPS | -0.44 | -0.35 | -0.43 | -0.84 | -1.10 |
| Average Basic Shares Outstanding | 211.76M | 192.43M | 169.55M | 147.94M | 126.65M |
| Average Diluted Shares Outstanding | 216.05M | 196.71M | 173.83M | 152.22M | 126.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |